RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells

Biochemical and Biophysical Research Communications

Volumn 348, Issue 1, 2006, Pages 153-157

  Materna, Verena ^a   Stege, Alexandra ^a   Surowiak, Pawel ^a   Priebsch, Axel ^a   Lage, Hermann ^a  

^a Charité Campus Benjamin Franklin Medical Center   (Germany)

Author keywords

ABC transporter; ABCC2; Cisplatin; cMOAT; Drug resistance; MRP2; Paclitaxel; RNAi

Indexed keywords

CARRIER PROTEIN; CISPLATIN; MESSENGER RNA; PACLITAXEL; PROTEIN; PROTEIN ABCC2; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OVARIAN NEOPLASMS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 33746709249     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.07.022     Document Type: Article

References (20)

1. Taniguchi K., Wada M., Kohno K., Nakamura T., Kawabe T., Kawakami M., Kagotani K., Okumura K., Akiyama S., and Kuwano M. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 56 (1996) 4124-4129
2. Koike K., Kawabe T., Tanaka T., Toh S., Uchiumi T., Wada M., Akiyama S., Ono M., and Kuwano M. A canalicular multispecific anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 57 (1997) 5475-5479
3. Kawabe T., Chen Z.S., Wada M., Uchiumi T., Ono M., Akiyama S., and Kuwano M. Enhanced transport of anticancer agents and leukotriene C4 by the human canalicular multispecific organic anion transporter (cMOAT/MRP2). FEBS Lett. 456 (1999) 327-331
4. Materna V., Liedert B., Thomale J., and Lage H. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int. J. Cancer 115 (2005) 393-402
5. Huisman M.T., Chhatta A.A., van Tellingen O., Beijnen J.H., and Schinkel A.H. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int. J. Cancer 116 (2005) 824-829
6. Lage H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int. J. Antimicrob. Agents 22 (2003) 188-199
7. Leier I., Jedlitschky G., Buchholz U., Cole S.P., Deeley R.G., and Keppler D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J. Biol. Chem. 269 (1994) 27807-27810
8. Lage H. MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr. Drug Targets 7 (2006) 813-821
9. Kowalski P., Surowiak P., and Lage H. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. Mol. Ther. 11 (2005) 508-522
10. Tian X., Zamek-Gliszczynski M.J., Zhang P., and Brouwer K.L. Modulation of multidrug resistance-associated protein 2 (Mrp2) and Mrp3 expression and function with small interfering RNA in sandwich-cultured rat hepatocytes. Mol. Pharmacol. 66 (2004) 1004-1010
11. Materna V., Holm P.S., Dietel M., and Lage H. Kinetic characterization of ribozymes directed against the cisplatin resistance-associated ABC-transporter cMOAT/MRP2/ABCC2. Cancer Gene Ther. 8 (2001) 176-184
12. Nieth C., Priebsch A., Stege A., and Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett. 545 (2003) 144-150
13. Stege A., Priebsch A., Nieth C., and Lage H. Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther. 11 (2004) 699-706
14. A. Priebsch, F. Rompe, H. Tönnies, P. Kowalski, P. Surowiak, A. Stege, V. Materna, H. Lage, Complete reversal of ABCG2-depending atypical multidrug resistance (MDR) by RNA interference in human carcinoma cells, Oligonucleotides (2006), in press.
15. Muratovska A., and Eccles M.R. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 558 (2004) 63-68
16. Liedert B., Materna V., Schadendorf D., Thomale J., and Lage H. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased G2-arrest in melanoma cells resistant to cisplatin. J. Invest. Dermatol. 121 (2003) 172-176
17. Nieth C., and Lage H. Induction of the ABC-transporters Mdr1/P-gp (Abcb1), mrp1(Abcc1), and bcrp (Abcg2) during establishment of multidrug resistance following exposure to mitoxantrone. J. Chemother. 17 (2005) 215-223
18. Surowiak P., Materna V., Kaplenko I., Spaczynski M., Dolinska-Krajewska B., Gebarowska E., Dietel M., Zabel M., and Lage H. Nuclear membraneous localization of ABCC2 (MRP2, cMOAT) in ovarian carcinoma cells can correlate with resistance to platinum-containing drugs and clinical outcome. Proc. Am. Assoc. Cancer Res. 47 (2006) 597
19. Zhang K., Mack P., and Wong K.P. Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int. J. Oncol. 12 (1998) 871-882
20. El-Deiry W.S. The role of p53 in chemosensitivity and radiosensitivity. Oncogene 22 (2003) 7486-7495